Sunesis Pharmaceuticals, Inc.  

(Public, NASDAQ:SNSS)   Watch this stock  
Find more results for SNSS
-0.05 (-1.94%)
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.51 - 2.64
52 week 1.00 - 8.45
Open 2.57
Vol / Avg. 1.67M/2.40M
Mkt cap 156.73M
P/E     -
Div/yield     -
EPS -0.84
Shares 61.95M
Beta 2.58
Inst. own 102%
Mar 4, 2015
Q4 2014 Sunesis Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 9, 2014
Sunesis Pharmaceuticals Inc to Discuss Presentation of Phase 3 VALOR Trial Results at ASH Annual Meeting
Nov 18, 2014
Sunesis Pharmaceuticals Inc at Stifel Healthcare Conference
Nov 12, 2014
Sunesis Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 10, 2014
Q3 2014 Sunesis Pharmaceuticals Inc Earnings Call - Webcast
Oct 6, 2014
Sunesis Pharmaceuticals, Inc. Corporate Update Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -1794.50% -434.87%
Operating margin -1558.66% -399.36%
EBITD margin - -399.11%
Return on average assets -116.24% -60.94%
Return on average equity -631.94% -1198.61%
Employees 32 -
CDP Score - -


Suite 400 395 Oyster Point Boulevard
United States - Map
+1-650-2663500 (Phone)
+1-650-2663501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Sunesis Pharmaceuticals, Inc. (Sunesis) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The Company is focuses primarily on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is a anti-cancer quinolone derivative (AQD). AQDs have been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. The Company owns worldwide development and commercialization rights to vosaroxin. The Company�s VALOR trial is designed to evaluate the effect of vosaroxin in combination with cytarabine, chemotherapy in AML. The trial has an adaptive design and is based on data from the Company's Phase II clinical trial of vosaroxin in combination with cytarabine in relapsed or refractory AML.

Officers and directors

Daniel N. Swisher Jr. President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Eric H. Bjerkholt Chief Financial Officer, Executive Vice President - Corporate Development and Finance
Age: 54
Bio & Compensation  - Reuters
Adam R. Craig M.D, Ph.D. Executive Vice President - Development, Chief Medical Officer
Age: 48
Bio & Compensation  - Reuters
Joseph I. DePinto Executive Vice President and Chief Commercial Officer
Age: 46
Bio & Compensation  - Reuters
James W. Young Ph.D. Non-Executive Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Stephen B. Ketchum Ph.D. Director
Age: 49
Bio & Compensation  - Reuters
Steve R. Carchedi Independent Director
Age: 52
Bio & Compensation  - Reuters
Matthew K Fust Independent Director
Age: 50
Bio & Compensation  - Reuters
Helen S. Kim Independent Director
Age: 51
Bio & Compensation  - Reuters